Anorexia Market

DelveInsight’s ‘Anorexia Nervosa-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Anorexia Nervosa, historical and forecasted epidemiology as well as the Anorexia Nervosa market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Anorexia Nervosa market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Anorexia Nervosa market size from 2019 to 2032. The Report also covers current Anorexia Nervosa treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Anorexia Nervosa Disease Understanding and Treatment Algorithm

Anorexia Nervosa Overview

Anorexia Nervosa (AN) is an eating disorder characterized by weight loss or lack of appropriate weight gain in growing children; difficulties maintaining an appropriate body weight for height, age, and stature; and, in many individuals, distorted body image. People with anorexia generally restrict the number of calories and the types of food they eat.

 

This disorder is characterized by deliberate weight loss, induced and sustained by the patient. It occurs most commonly in adolescent girls and young women, but adolescent boys and young men may also be affected, as many children approaching puberty and older women up to the menopause. The disorder is associated with specific psychopathology whereby a dread of fatness and flabbiness of body contour persists as an intrusive, overvalued idea, and the patients impose a low weight threshold on themselves. There is usually under nutrition of varying severity with secondary endocrine and metabolic changes and disturbances of bodily function. The symptoms include restricted dietary choice, excessive exercise, induced vomiting and purgation, and use of appetite suppressants and diuretic

 

Eating disorders are not a choice but are serious mental illnesses and can significantly impact all aspects of a person’s life – physical, emotional, and social. The earlier an eating disorder is identified and a person can access treatment, the greater the opportunity for recovery or improved quality of life.

 

Anorexia Nervosa Diagnosis

No objective test—such as bloodwork or an X-ray—can definitively point to an eating disorder. Instead, a doctor makes the diagnosis based on a person’s symptoms. To diagnose anorexia, the doctor will ask about the person’s symptoms, and they may also ask family members and other loved ones about their observations. If a doctor believes that a person has anorexia, they will attempt to diagnose the type. One type primarily involves restricting food intake, while another involves episodes of overeating and purging. If the person has experienced at least one of these episodes in the past 3 months, the doctor will likely diagnose binge eating and purging anorexia.

 

Diagnostic instruments in the form of questionaires are used. Few of them are as follows:

  • Structured Inventory for Anorexic and Bulimic Eating Disorders Self-Report (SIAB-S)
  • Munich Eating and Feeding Disorder Questionnaire (Munich ED-Quest)
  • Eating Disorder Examination-Questionnaire for children (ChEDE-Q)
  • The SCOFF questionnaire

Continued in the report…..

 

Anorexia Nervosa Treatment

Treatment for anorexia must address both psychological and physical problems. The treatment team should include a mental health professional and a primary care doctor.

 

Successful treatment usually includes continuous medical care, regular therapy, nutritional counseling, and medication. Although certain antidepressants are sometimes used to treat anorexia, they are not always effective, and no medication is FDA approved to treat it. Doctors should pay attention to bone loss, electrolyte levels in the blood, and heart function. Psychologists and other mental health professionals can help a person let go of self-destructive thoughts and behaviors and adopt a more positive outlook. Support groups of other recovering anorexics -- when properly moderated by a mental health professional -- can also be very helpful. Treatment usually is successful, but it does not work overnight. Long-term psychological and medical attention usually is needed.

Continued in the report…..

Anorexia Nervosa Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Anorexia Nervosa, diagnosed prevalent cases of Anorexia Nervosa and gender-specific diagnosed prevalent cases of Anorexia Nervosa scenario of Anorexia Nervosa in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • Total prevalent cases of Anorexia Nervosa in the 7MM were found to be approximately 1,692,817 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.3% during the study period (2019–2032).
  • Among 7MM, the United States has the highest prevalent cases of Anorexia Nervosa with 703,497 cases in 2021.
  • The total diagnosed prevalent cases of Anorexia Nervosa in the 7MM were observed to be 812,552 in 2021. These cases are expected to increase during the study period (2019–2032).
  • Among the European countries, Germany had the highest diagnosed prevalent population of Anorexia Nervosa with 86,928 cases, followed by the UK with 69,732 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
  • In Japan, 128,408 diagnosed prevalent cases of Anorexia Nervosa were recorded in the year 2021.
  • As per DelveInsight’s assessment, for Anorexia Nervosa, the gender-specific distribution of the disease suggests females at a higher count with 763,335 cases in the 7MM, in 2021.

Country-Wise Anorexia Nervosa Epidemiology

The epidemiology segment also provides the Anorexia Nervosa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anorexia Nervosa Drug Chapters

The drug chapter segment of the Anorexia Nervosa report encloses the detailed analysis of Anorexia Nervosa marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Anorexia Nervosa clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

 

Anorexia Nervosa Emerging Drugs

 

Psilocybin: COMPASS Pathways

Psilocybin is a serotonin 2 receptor agonist, being developed by COMPASS Pathways, for treatment-resistant depression, including major depressive disorder, depressive disorders, bipolar depression, body dysmorphic disorder (somatoform disorders in developmental table), and Anorexia Nervosa. It is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms. Currently, a Phase II trial is expected to complete in 2022 showing the effect of psilocybin-assisted psychotherapy in patients with AN.

 

Ketamine: Homeostasis Therapeutics, LLC

Ketamine has rapid antidepressant effects, which are hypothesized to occur via increases in glutamate, with sequelae including increased neuroplasticity, neurogenesis, and synaptogenesis. It is an N-methyl-D-aspartate receptor (NMDAr) antagonist, recently been approved for treatment-resistant depression, exerting rapid and robust antidepressant effects. It is now being investigated for several indications, including obsessive-compulsive, post-traumatic, and substance use disorder, and shows trans diagnostic potential for EDs, particularly among clinical nonresponders.

Products detail in the report…

List of products to be continued in the report…

Anorexia Nervosa Market Outlook

Anorexia Nervosa (AN) has a diverse genetic disposition as well as is being determined by life phases such as puberty, problems in the family or with peers, trauma, and personality traits such as low self-esteem. It is characterized by extreme food restriction and an intense fear of gaining weight. Treatment usually involves several strategies, including psychological therapy, nutritional counseling, and/or hospitalization.

 

Treatment plans are tailored to individual needs and may include one or more of the following:

  • The individual, group, and/or family psychotherapy
  • Medical care and monitoring
  • Nutritional counseling
  • Medications

 

Psychotherapies generally include Family-based treatment (FBT), Eating disorder-focused, Adolescent-focused psychotherapy, and others

 

Medications such as antidepressants, antipsychotics, or mood stabilizers may also be helpful for the treatment of eating disorders and other co-occurring illnesses such as anxiety or depression. Medications like olanzapine, aripiprazole, and dronabinol are generally used to manage the patients, but there is no standard therapy available. Quetiapine is an atypical antipsychotic that, in low dose, can help with both psychological and physical improvements, with minimal associated side effects, and appears to be a promising candidate for the treatment of AN. Prozac can help with depressive symptoms and potentially with healthy weight maintenance once weight restoration is achieved. Prozac is part of the SSRI family or the selective serotonin uptake inhibitors that assist with increased serotonin levels connected to mood.

 

Key Findings

  • The market size of Anorexia Nervosa in seven major markets was USD 63 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 18.9% for the study period (2019–2032)
  • The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Anorexia Nervosa.
  • Upcoming therapy such as Psilocybin has the potential to create a significant positive shift in the Anorexia Nervosa market size.
  • The United States accounts for the largest market size of Anorexia Nervosa, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

 

The United States Market Outlook

This section provides the total Anorexia Nervosa market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total Anorexia Nervosa market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Anorexia Nervosa market size and market size by therapies in Japan are provided.

Anorexia Nervosa Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Anorexia Nervosa market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Anorexia Nervosa market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Anorexia Nervosa Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Anorexia Nervosa emerging therapies.

Reimbursement Scenario in Anorexia Nervosa

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitively and market Intelligence analysis of the Anorexia Nervosa market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Anorexia Nervosa, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Anorexia Nervosa epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Anorexia Nervosa is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Anorexia Nervosa market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Anorexia Nervosa market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Anorexia Nervosa market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anorexia Nervosa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Anorexia Nervosa. The launch of emerging therapies will significantly impact the Anorexia Nervosa market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Anorexia Nervosa Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Anorexia Nervosa Pipeline Analysis
  • Anorexia Nervosa Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Anorexia Nervosa Report Key Strengths

  • 11-Years Forecast
  • The 7MM Coverage
  • Anorexia Nervosa Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Anorexia Nervosa Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Anorexia Nervosa market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Anorexia Nervosa total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Anorexia Nervosa market size during the forecast period (2022–2032)?
  • At what CAGR, the Anorexia Nervosa market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Anorexia Nervosa market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Anorexia Nervosa market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Anorexia Nervosa?
  • What is the historical Anorexia Nervosa patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Anorexia Nervosa at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Anorexia Nervosa?
  • Out of the above-mentioned countries, which country would have the highest population of Anorexia Nervosa during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Anorexia Nervosa along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Anorexia Nervosa in the US and Europe?
  • What are the Anorexia Nervosa marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Anorexia Nervosa?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Anorexia Nervosa?
  • What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Anorexia Nervosa therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anorexia Nervosa and their status?
  • What are the key designations that have been granted for the emerging therapies for Anorexia Nervosa?
  • What are the 7MM historical and forecasted market of Anorexia Nervosa?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Anorexia Nervosa.
  • To understand the future market competition in the Anorexia Nervosa market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Anorexia Nervosa in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Anorexia Nervosa market.
  • To understand the future market competition in the Anorexia Nervosa market.

1. Key Insights

2. Report Introduction

3. Anorexia Nervosa Market Overview at a Glance

3.1. Market Share (%) Distribution of Anorexia Nervosa by Therapies in 2019

3.2. Market Share (%) Distribution of Anorexia Nervosa by Therapies in 2032

4. Anorexia Nervosa Market: Future Perspective

5. Executive Summary of Anorexia nervosa

6. Disease Background and Overview: Anorexia Nervosa (AN)

6.1. Introduction of Anorexia Nervosa

6.2. Types of Anorexia Nervosa

6.3. Risk factors of Anorexia Nervosa

6.4. Symptoms of Anorexia Nervosa

6.5. Comorbidities of Anorexia Nervosa

6.6. Etiology of Anorexia Nervosa

6.7. Pathophysiology of Anorexia Nervosa

6.8. Diagnostic Approach of Anorexia Nervosa

6.8.1. Diagnostic Guidelines

6.8.1.1. DSM-5 Diagnostic Criteria

6.8.1.2. ICD-11 diagnostic criteria (6B10)

6.8.1.3. ICD-10 diagnostic criteria (FB50.0)

6.8.1.4. German Guidelines on Fluency Disorders based on ICF mode

6.9. Treatment and Management of Anorexia Nervosa

6.9.1. Treatment Algorithm

6.9.2. Treatment Guidelines

6.9.2.1. AAFP Key Recommendations:

6.9.2.2. German Guidelines

6.9.2.3. WFSBP Guidelines for the Pharmacological Treatment of Eating Disorders

6.9.2.4. APA Practice Guidelines

6.9.2.5. NICE Guidelines

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology of Epidemiology

7.3. Assumptions and Rationale: 7MM

7.4. Total Prevalent Cases of Anorexia Nervosa in the 7MM

7.5. Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM

7.6. The United States

7.6.1. Total Prevalent Cases of Anorexia Nervosa in the United States

7.6.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in the United States

7.6.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US

7.7. Major Five European Countries

7.7.1 Germany

7.7.1.1. Total Prevalent Cases of Anorexia Nervosa in Germany

7.7.2.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany

7.7.3.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany

7.7.2. France

7.7.2.1. Total Prevalent Cases of Anorexia Nervosa in France

7.7.2.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in France

7.7.2.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France

7.7.3. Italy

7.7.3.1. Total Prevalent Cases of Anorexia Nervosa in Italy

7.7.3.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy

7.7.3.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy

7.7.4. Spain

7.7.4.1. Total Prevalent Cases of Anorexia Nervosa in Spain

7.7.4.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain

7.7.4.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain

7.7.5. UK

7.7.5.1. Total Prevalent Cases of Anorexia Nervosa in the UK

7.7.5.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK

7.7.5.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK

7.8. Japan

7.8.1. Total Prevalent Cases of Anorexia Nervosa in Japan

7.8.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan

7.8.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan

8. Patient Journey

9. Emerging Drugs

9.1. Key Cross Competition

9.2. Psilocybin: COMPASS Pathways

9.2.1. Product Description

9.2.2. Other Development Activities

9.2.3. Clinical Development

9.2.4. Clinical Trials Information

9.2.5. Safety and Efficacy

9.2.6. Product Profile

9.2.7. Analysts’ Views

9.3. Ketamine: Homeostasis Therapeutics, LLC

9.3.1. Product Description

9.3.2. Other Development Activities

9.3.3. Clinical Development

9.3.4. Clinical Trials Information

9.3.5. Product Profile

10. Anorexia nervosa: Seven Major Market Analysis

10.1. Key Findings

10.2. Methodology of Anorexia nervosa Market

10.3. Market Outlook

10.4. Potential of Emerging Therapies

10.5. Key Market Forecast Assumptions

10.6. Market Size of Anorexia Nervosa in the 7MM

10.7. Market Size of Anorexia Nervosa by Therapies in the 7MM

10.8. Market Size of Anorexia Nervosa in the United States

10.8.1. Total Market Size of Anorexia Nervosa

10.8.2. Market Size of Anorexia Nervosa by Therapies

10.9. Market Size of Anorexia Nervosa in the EU-5

10.9.1.  Market Size of Anorexia Nervosa in the Germany

10.9.1.1. Total Market Size of Anorexia Nervosa

10.9.1.2. Market Size of Anorexia Nervosa by Therapies

10.9.2. Market Size of Anorexia Nervosa in the France

10.9.2.1. Total Market Size of Anorexia Nervosa

10.9.2.2. Market Size of Anorexia Nervosa by Therapies

10.9.3. Market Size of Anorexia Nervosa in the Italy

10.9.3.1. Total Market Size of Anorexia Nervosa

10.9.3.2. Market Size of Anorexia Nervosa by Therapies

10.9.4. Market Size of Anorexia Nervosa in the Spain

10.9.4.1. Total Market Size of Anorexia Nervosa

10.9.4.2. Market Size of Anorexia Nervosa by Therapies

10.9.5. Market Size of Anorexia Nervosa in the UK

10.9.5.1. Total Market Size of Anorexia Nervosa

10.9.5.2. Market Size of Anorexia Nervosa by Therapies

10.10. Market Size of Anorexia Nervosa in Japan

10.10.1. Total Market Size of Anorexia Nervosa

10.10.2. Market Size of Anorexia Nervosa by Therapies

11. Key Opinion Leaders’ Views

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Unmet Needs

16. Reimbursement and Market Access

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of AN Market and Epidemiology (2019–2032)

Table 2: Severity Specific Classification

Table 3: Total Prevalent Cases of Anorexia Nervosa In the 7MM, in ‘000’ (2019–2032)

Table 4: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM, in ‘000’ (2019–2032)

Table 5: Total Prevalent Cases of Anorexia Nervosa in the US, in ‘000’ (2019–2032)

Table 6: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the US, in ‘000’ (2019–2032)

Table 7: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US, in ‘000’ (2019–2032)

Table 8: Total Prevalent Cases of Anorexia Nervosa in Germany, in ‘000’ (2019–2032)

Table 9: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany, in ‘000’ (2019–2032)

Table 10: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany, in ‘000’ (2019–2032)

Table 11: Total Prevalent Cases of Anorexia Nervosa in France, in ‘000’ (2019–2032)

Table 12: Total Diagnosed Prevalent Cases of Anorexia Nervosa in France, in ‘000’ (2019–2032)

Table 13: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France, in ‘000’ (2019–2032)

Table 14: Total Prevalent Cases of Anorexia Nervosa in Italy, in ‘000’ (2019–2032)

Table 15: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy, in ‘000’ (2019–2032)

Table 16: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy, in ‘000’ (2019–2032)

Table 17: Total Prevalent Cases of Anorexia Nervosa in Spain, in ‘000’ (2019–2032)

Table 18: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain, in ‘000’ (2019–2032)

Table 19: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain, in ‘000’ (2019–2032)

Table 20: Total Prevalent Cases of Anorexia Nervosa in the UK, in ‘000’ (2019–2032)

Table 21: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK, in ‘000’ (2019–2032)

Table 22: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK, in ‘000’ (2019–2032)

Table 23: Total Prevalent Cases of Anorexia Nervosa in Japan, in ‘000’ (2019–2032)

Table 24: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan, in ‘000’ (2019–2032)

Table 25: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan, in ‘000’ (2019–2032)

Table 26: Comparison of emerging drugs under development

Table 27: Psilocybin, Clinical Trial Description, 2022

Table 28: Ketamine, Clinical Trial Description, 2022

Table 29: Key Market Forecast Assumptions for Psilocybin

Table 30: Market Size of Anorexia Nervosa in the 7MM in USD Million (2019–2032)

Table 31: Market Size of Anorexia Nervosa by Therapies in the 7MM in USD Million (2019–2032)

Table 32: United States Market Size of Anorexia Nervosa in USD Million (2019–2032)

Table 33: Market Size of Anorexia Nervosa by Therapies in the US in USD Million (2019–2032)

Table 34: EU-5 Market Size of Anorexia Nervosa, in USD Million (2019–2032)

Table 35: Market Size of Anorexia Nervosa by Therapies in the EU5, in USD Million (2019–2032)

Table 36: Market size of Anorexia Nervosa in Germany, in USD Million (2019-2032)

Table 37: Market Size of Anorexia Nervosa by Therapies in Germany, in USD Million (2019–2032)

Table 38: Market size of Anorexia Nervosa in France, in USD Million (2019-2032)

Table 39: Market Size of Anorexia Nervosa by Therapies in France, in USD Million (2019–2032)

Table 40: Market size of Anorexia Nervosa in Italy, in USD Million (2019-2032)

Table 41: Market Size of Anorexia Nervosa by Therapies in Italy, in USD Million (2019–2032)

Table 42: Market size of Anorexia Nervosa in Spain, in USD Million (2019-2032)

Table 43: Market Size of Anorexia Nervosa by Therapies in Spain, in USD Million (2019–2032)

Table 44: Market size of Anorexia Nervosa in UK, in USD Million (2019-2032)

Table 45: Market Size of Anorexia Nervosa by Therapies in the UK, in USD Million (2019–2032)

Table 46: Market Size of Anorexia Nervosa in Japan, in USD Million (2019–2032)

Table 47: Market Size of Anorexia Nervosa by Therapies in Japan, in USD Million (2019–2032)

List of Figures

Figure 1: Types of Eating Disorder

Figure 2: Types of Anorexia Nervosa

Figure 3: Physical Signs and Effects of Anorexia Nervosa

Figure 4: Medical Complications

Figure 5: Psychiatric Comorbidity

Figure 6: Stepwise approach to managing Anorexia Nervosa

Figure 7: Key Strategies for Treatment of AN

Figure 8: Phases of FBT

Figure 9: Phases of FPT

Figure 10: Anorexia Nervosa Treatment Algorithm

Figure 11: Total Prevalent Cases of Anorexia Nervosa In the 7MM, in ‘000’ (2019–2032)

Figure 12: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM, in ‘000’ (2019–2032)

Figure 13: Total Prevalent Cases of Anorexia Nervosa in the United States, in ‘000’ (2019–2032)

Figure 14: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the US, in ‘000’ (2019–2032)

Figure 15: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US, in ‘000’ (2019–2032)

Figure 16: Total Prevalent Cases of Anorexia Nervosa in Germany, in ‘000’ (2019–2032)

Figure 17: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany, in ‘000’ (2019–2032)

Figure 18: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany, in ‘000’ (2019–2032)

Figure 19: Total Prevalent Cases of Anorexia Nervosa in France, in ‘000’ (2019–2032)

Figure 20: Total Diagnosed Prevalent Cases of Anorexia Nervosa in France, in ‘000’ (2019–2032)

Figure 21: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France, in ‘000’ (2019–2032)

Figure 22: Total Prevalent Cases of Anorexia Nervosa in Italy, in ‘000’ (2019–2032)

Figure 23: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy, in ‘000’ (2019–2032)

Figure 24: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy, in ‘000’ (2019–2032)

Figure 25: Total Prevalent Cases of Anorexia Nervosa in Spain, in ‘000’ (2019–2032)

Figure 26: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain, in ‘000’ (2019–2032)

Figure 27: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain, in ‘000’ (2019–2032)

Figure 28: Total Prevalent Cases of Anorexia Nervosa in the UK, in ‘000’ (2019–2032)

Figure 29: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK, in ‘000’ (2019–2032)

Figure 30: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK, in ‘000’ (2019–2032)

Figure 31: Total Prevalent Cases of Anorexia Nervosa in Japan, in ‘000’ (2019–2032)

Figure 32: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan, in ‘000’ (2019–2032)

Figure 33: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan, in ‘000’ (2019–2032)

Figure 34: Patient Journey

Figure 35: Market Size of Anorexia Nervosa in the 7MM, in USD Million (2019–2032)

Figure 36: Market Size of Anorexia Nervosa by Therapies in the 7MM in USD Million (2019–2032)

Figure 37: Market Size of Anorexia Nervosa in the United States, USD Million (2019–2032)

Figure 38: Market Size of Anorexia Nervosa by Therapies in the United States, in USD Million (2019–2032)

Figure 39: Market Size of Anorexia Nervosa in the EU-5, USD Million (2019–2032)

Figure 40: Market Size of Anorexia Nervosa by Therapies, in the EU-5, in USD Million (2019–2032)

Figure 41: Market size of Anorexia Nervosa in Germany, in USD Million (2019-2032)

Figure 42: Market Size of Anorexia Nervosa by Therapies in Germany, in USD Million (2019–2032)

Figure 43: Market size of Anorexia Nervosa in France, in USD Million (2019-2032)

Figure 44: Market Size of Anorexia Nervosa by Therapies in France, in USD Million (2019–2032)

Figure 45: Market size of Anorexia Nervosa in Italy, in USD Million (2019-2032)

Figure 46: Market Size of Anorexia Nervosa by Therapies in Italy, in USD Million (2019–2032)

Figure 47: Market size of Anorexia Nervosa in Spain, in USD Million (2019-2032)

Figure 48: Market Size of Anorexia Nervosa by Therapies in Spain, in USD Million (2019–2032)

Figure 49: Market size of Anorexia Nervosa in UK, in USD Million (2019-2032)

Figure 50: Market Size of Anorexia Nervosa by Therapies in the UK, in USD Million (2019–2032)

Figure 51: Market Size of Anorexia Nervosa in Japan, USD Million (2019–2032)

Figure 52: Market Size of Anorexia Nervosa by Therapies in Japan, in USD Million (2019–2032)

Figure 53: Market Drivers

Figure 54: Market Barriers

Figure 55: SWOT Analysis

Figure 56: Unmet Needs

COMPASS Pathways
Homeostasis Therapeutics, LLC

 

Forward to Friend

Need A Quote